Literature DB >> 25348897

Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.

J Darbà1, L Kaskens2, L Lacey3.   

Abstract

OBJECTIVE: The objectives of this analysis were to examine how patients' global severity with Alzheimer's disease (AD) relates to costs of care and explore the incremental effects of global severity measured by the clinical dementia rating (CDR) scale on these costs for patients in Spain.
METHODS: The Codep-EA study is an 18-multicenter, cross-sectional, observational study among patients (343) with AD according to the CDR score and their caregivers in Spain. The data obtained included (in addition to clinical measures) also socio-demographic data concerning the patient and its caregiver. Cost analyses were based on resource use for medical care, social care, caregiver productivity losses, and informal caregiver time reported in the resource utilization in dementia (RUD). Lite instrument and a complementary questionnaire. Multivariate regression analysis was used to model the effects of global severity and other socio-demographic and clinical variables on cost of care.
RESULTS: The mean (standard deviation) costs per patient over 6 months for direct medical, social care, indirect and informal care costs, were estimated at €1,028.1 (1,655.0), €843.8 (2,684.8), €464.2 (1,639.0) and €33,232.2 (30,898.9), respectively. Dementia severity, as having a CDR score 0.5, 2, or 3 with CDR score 1 being the reference group were all independently and significantly associated with informal care costs. Whereas having a CDR score of 2 was also significantly related with social care costs, a CDR score of 3 was associated with most cost components including direct medical, social care, and total costs, all compared to the reference group.
CONCLUSIONS: The costs of care for patients with AD in Spain are substantial, with informal care accounting for the greatest part. Dementia severity, measured by CDR score, showed that with increasing severity of the disease, direct medical, social care, informal care and total costs augmented.

Entities:  

Keywords:  Alzheimer; Clinical dementia rating scale; Direct medical costs; Indirect costs; Informal care costs; Social care costs

Mesh:

Year:  2014        PMID: 25348897     DOI: 10.1007/s10198-014-0642-0

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  24 in total

1.  The cost of Alzheimer's disease in managed care: a cross-sectional study.

Authors:  J Leon; P J Neumann
Journal:  Am J Manag Care       Date:  1999-07       Impact factor: 2.229

2.  Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  L Fratiglioni; L J Launer; K Andersen; M M Breteler; J R Copeland; J F Dartigues; A Lobo; J Martinez-Lage; H Soininen; A Hofman
Journal:  Neurology       Date:  2000       Impact factor: 9.910

3.  Clinical Dementia Rating (CDR).

Authors:  L Berg
Journal:  Psychopharmacol Bull       Date:  1988

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.

Authors:  Jens Peter Reese; Philipp Hessmann; Greta Seeberg; Dajana Henkel; Pamela Hirzmann; Jürgen Rieke; Erika Baum; Frank Dannhoff; Matthias J Müller; Frank Jessen; Monika-Balzer Geldsetzer; Richard Dodel
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  The use of proxy respondents in studies of older adults: lessons, challenges, and opportunities.

Authors:  P J Neumann; S S Araki; E M Gutterman
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

7.  A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients.

Authors:  Fabio Salvi; Mark D Miller; Annalisa Grilli; Raffaella Giorgi; Adele L Towers; Valeria Morichi; Liana Spazzafumo; Lucia Mancinelli; Emma Espinosa; Alessandro Rappelli; Paolo Dessì-Fulgheri
Journal:  J Am Geriatr Soc       Date:  2008-09-22       Impact factor: 5.562

8.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

9.  Relation between severity of Alzheimer's disease and costs of caring.

Authors:  M J Hux; B J O'Brien; M Iskedjian; R Goeree; M Gagnon; S Gauthier
Journal:  CMAJ       Date:  1998-09-08       Impact factor: 8.262

10.  Predictors of costs in dementia in a longitudinal perspective.

Authors:  Hanna Leicht; Hans-Helmut König; Nina Stuhldreher; Cadja Bachmann; Horst Bickel; Angela Fuchs; Kathrin Heser; Frank Jessen; Mirjam Köhler; Melanie Luppa; Edelgard Mösch; Michael Pentzek; Steffi Riedel-Heller; Martin Scherer; Jochen Werle; Siegfried Weyerer; Birgitt Wiese; Wolfgang Maier
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

View more
  10 in total

1.  Costs of dementia in the Czech Republic.

Authors:  Iva Holmerová; Jakub Hort; Robert Rusina; Anders Wimo; Michal Šteffl
Journal:  Eur J Health Econ       Date:  2016-10-26

2.  Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study.

Authors:  Erik Meijer; Maria Casanova; Hyewon Kim; Ana Llena-Nozal; Jinkook Lee
Journal:  Lancet Reg Health Eur       Date:  2022-06-24

Review 3.  The Humanistic and Economic Burden of Alzheimer's Disease.

Authors:  Amir Abbas Tahami Monfared; Michael J Byrnes; Leigh Ann White; Quanwu Zhang
Journal:  Neurol Ther       Date:  2022-02-22

4.  Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.

Authors:  Alan Lenox-Smith; Catherine Reed; Jeremie Lebrec; Mark Belger; Roy W Jones
Journal:  BMC Geriatr       Date:  2016-11-25       Impact factor: 3.921

5.  The cost of dementia in an unequal country: The case of Chile.

Authors:  Daniel A Hojman; Fabian Duarte; Jaime Ruiz-Tagle; Marilu Budnich; Carolina Delgado; Andrea Slachevsky
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

6.  Detection, diagnosis, and treatment of Alzheimer's disease dementia stratified by severity as reported by caregivers in Japan.

Authors:  William Montgomery; Amir Goren; Kristin Kahle-Wrobleski; Tomomi Nakamura; Kaname Ueda
Journal:  Neuropsychiatr Dis Treat       Date:  2018-07-16       Impact factor: 2.570

7.  Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).

Authors:  Aina Soler; Guillem Amer; Alicia Leiva; Joana Ripoll; María Angeles Llorente; Alfonso Leiva; Joana Maria Taltavull; Rosa Molina; Joan Llobera
Journal:  BMC Geriatr       Date:  2019-04-11       Impact factor: 3.921

8.  Short-term memory, attention, and temporal orientation as predictors of the cognitive impairment in older adults: A cross-sectional observational study.

Authors:  Isabel Gómez-Soria; Chelo Ferreira; Bárbara Oliván Blazquez; Rosa Mª Magallón Botaya; Estela Calatayud
Journal:  PLoS One       Date:  2021-12-20       Impact factor: 3.240

9.  Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.

Authors:  Virginie Dauphinot; Michele Potashman; Mihaela Levitchi-Benea; Ray Su; Ivana Rubino; Pierre Krolak-Salmon
Journal:  Alzheimers Res Ther       Date:  2022-02-12       Impact factor: 6.982

10.  Comorbid Pain and Cognitive Impairment in a Nationally Representative Adult Population: Prevalence and Associations With Health Status, Health Care Utilization, and Satisfaction With Care.

Authors:  Richard L Nahin; Steven T DeKosky
Journal:  Clin J Pain       Date:  2020-10       Impact factor: 3.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.